The T2Sepsis SolutionTM is a unique approach that combines the best standard of care for the management of sepsis patients with T2 Biosystems’ products, including the T2Dx® Instrument and T2Candida® Panel, and the T2Bacteria® Panel, which is commercially available in Europe and other countries that accept the CE mark.
Powered by T2 Magnetic Resonance (T2MR®) technology, the T2Sepsis Solution enables faster and more accurate testing for the detection of sepsis-causing pathogens than previously possible. The advantage of T2MR, based on results from the proven T2Candida Panel, is clear: highly accurate results with a sensitivity greater than 90% are available in just hours, not days.1
Proven to deliver better patient care and greater cost savings
Run on the T2Dx Instrument, the T2Candida Panel targets Candida, one of the deadliest sepsis-causing pathogens. In fact, it is known to have a staggering 40% mortality rate, and costs healthcare systems an average of $130,000 (€111,000/£100,000) per patient.2,3 The T2Dx Instrument is currently available in approximately 130 hospitals in the United States and Europe.
Expanding the T2Sepsis Solution to include the T2Bacteria Panel
The T2Sepsis Solution is expanding to include the T2Bacteria Panel, which is now CE marked in the EU and will be commercially available in the third quarter 2017.
Thanks to the aggressive efforts of clinicians and hospitals, about 60% of symptomatic patients today are on the appropriate antimicrobial therapy within the critical 12-hour window. But the limitations of current diagnostic technology leave about 40% of patients waiting too long for the right diagnosis and treatment.
The combined results from the T2Candida and T2Bacteria Panels—along with empiric antimicrobial therapy—will enable up to 95% of patients to receive effective therapy within those first critical 6 hours.9,10
Sepsis – a serious public health crisis
Sepsis is one of the greatest challenges facing hospitals today. Sepsis contributes to nearly one in two hospital deaths.11 In fact, it is the most expensive hospital-treated condition in the U.S., representing $27B in U.S. healthcare costs,12,13 and it is the most frequent cause of hospital readmissions.14 The UK sees 147,000 cases diagnosed each year, contributing to 42,000 deaths15 and £2 billion in sepsis-related costs.16 It is their #2 killer after cardiovascular disease and claims more lives than lung cancer annually.17
Treating patients at risk of sepsis effectively—a major unmet need in healthcare
There are over 100 drugs that combat sepsis-causing pathogens; the greatest challenge for clinicians is to quickly identify the sepsis-causing pathogen and administer targeted treatment. The underlying problem? All current diagnostics rely on blood culture. However, culturing blood can take up to 5 days and misses up to half of infections.18 When nearly half of patients are missed in the critical first step, even the most accurate downstream blood-culture-reliant diagnostics cannot detect what blood culture missed.
No-blood-culture detection—the future of sepsis diagnostics is here today
Research has shown that the mortality rate for sepsis, if left unmanaged, rises by 8% every hour.19 Information to help clinicians target treatment in hours, not days, is the key to making a real difference in outcomes for patients with sepsis.
At T2, our mission is to save lives and improve healthcare. We believe that having the greatest impact on patients and their families requires a new approach that detects sepsis-causing pathogens directly from whole blood, without a blood culture.
1. Mylonakis, E., Clancy, C. J., Ostrosky-Zeichner, L., Garey, K. W., Alangaden, G. J., Vazquez, J. A., … & Zervou, F. N. (2015). T2 magnetic resonance assay for the rapid diagnosis of candidemia in whole blood: a clinical trial. Clinical Infectious Diseases, ciu959.
2. Parkins, M. D., et al. (2007). Journal of Antimicrobial Chemotherapy, 60(3), 613-618.
3. Gagne, J. J., Breitbart, R. E., Maio, V.,et. al. (2006). Costs associated with candidemia in a hospital setting. P and T, 31(10), 586.
4. Wilson, N.M., Kenney, R.M., Tibbetts, R.J., et. al. T2 Magnetic Resonance Improves the Timely Management of Candidemia. Poster Presentation IDWeek 2016.
5. Estrada, S. J. Real World Value of T2Candida Lee Memorial Hospital. Slide Presentation ASM 2016.
6. Kirn, T.J. T2Candida Assay Implementation at Robert Wood Johnson University Hospital. Slide Presentation ASM Microbe 2017.
7. Patel F, Young E. Antifungal Prescribing During Initial Implementation of Candidemia Early Detection and Species Identification Testing with T2Candida Panel. Poster Presentation IDWeek 2016.
8. Kateon H et al. Utilization of T2Candida Panel for the rapid detection of Candida species in a large community hospital. Poster Presentation IDWeek 2016.
9. Buehler, S. S., Madison, B., Snyder, S. R., Derzon, J. H., Cornish, N. E., Saubolle, M. A., … & Wolk, D. M. (2016). Effectiveness of practices to increase timeliness of providing targeted therapy for inpatients with bloodstream infections: a laboratory medicine best practices systematic review and meta-analysis. Clinical microbiology reviews, 29(1), 59-103.
10. Kumar, A., Ellis, P., Arabi, Y., Roberts, D., Light, B., Parrillo, J. E., … & Peters, C. (2009). Initiation of inappropriate antimicrobial therapy results in a fivefold reduction of survival in human septic shock. CHEST Journal, 136(5), 1237-1248.
11. Liu, V., Escobar, G. J., Greene, J. D., Soule, J., Whippy, A., Angus, D. C., & Iwashyna, T. J. (2014). Hospital deaths in patients with sepsis from 2 independent cohorts. Jama, 312(1), 90-92.
12. Torio, C. M., Moore, B. J. (2016). Statistical Brief# 204. Healthcare Cost and Utilization Project (HCUP). May.
13. McDermott, K. W., Elixhauser, A., Sun, R. (2017). Statistical Brief# 225. Healthcare Cost and Utilization Project (HCUP). June.
14. Mayr, F. B., Talisa, V. B., Balakumar, V., Chang, C. C. H., Fine, M., & Yende, S. (2017). Proportion and cost of unplanned 30-day readmissions after sepsis compared with other medical conditions. Jama, 317(5), 530-531.
15. Hex, Nick et al. The Cost of Sepsis Care in the UK. 2017.
16. Vincent, J., et al. “Sepsis in European intensive care units: results of the SOAP study.” Critical Care Medicine-Baltimore- 34.2 (2006): 344.
17. Daniels R. Surviving the first hours in sepsis: getting the basics right (an intensivist’s perspective). Journal of Antimicrobial Chemotherapy. 2011 Apr 1;66(suppl 2):ii11-23.
18. Clancy, C. J., & Nguyen, M. H. (2013). Finding the “missing 50%” of invasive candidiasis: how nonculture diagnostics will improve understanding of disease spectrum and transform patient care. Clinical infectious diseases, 56(9), 1284-1292.
19. Kumar, A., Roberts, D., Wood, K. E., Light, B., Parrillo, J. E., Sharma, S., … & Gurka, D. (2006). Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Critical care medicine, 34(6), 1589-1596.